APP’s new labeling represents further enhancements to help differentiate Heparin Sodium from other heparin products, including Heparin Lock Flush Solution, USP. Product with the new labeling will begin arriving at hospitals and dialysis centers nationwide the week of June 2, 2008.
As part of the company’s long-standing commitment to patient care and in response to concerns regarding a higher risk of medication errors associated with heparin, the new labeling will further help healthcare professionals quickly identify the correct drug and ultimately administer the proper dose.
Heparin is indicated for anticoagulant therapy for patients undergoing surgery, blood transfusions, extracorporeal circulation, dialysis procedures and other settings that require a blood-clotting inhibitor.